Vericel (VCEL) Notes Payables (2013 - 2014)

Vericel's (VCEL) quarterly Notes Payables came in at $2.5 million in Q2 2014, up 41566.67% quarter-over-quarter from $6000.0 in Q4 2013.

Vericel (VCEL) Notes Payables (2013 - 2014) Analysis & Trends

Vericel has disclosed Notes Payables across 2 years of filings, most recently posting $2.5 million for Q2 2014.

Notes Payables for Q2 2014 came in at $2.5 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2014 was $2.5 million (changed N/A YoY), and the FY2013 annual result was $6000.0, changed N/A from the prior year.
Notes Payables came in at $2.5 million for Q2 2014 at Vericel, up from $6000.0 in the prior quarter.
In the past five years, Notes Payables ranged from a high of $2.5 million in Q2 2014 to a low of $6000.0 in Q4 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Vericel	2.04 Bn	1.90 Bn	49.27 Mn

Download Data

Date	Value
Jun 30, 2014	2.50 Mn
Dec 31, 2013	6,000.00